Stereotaxis, Inc.
NYSEAM:STXS Voorraadrapport
Marktkapitalisatie: US$161.1m
Stereotaxis Dividenden en inkoop
Dividend criteriumcontroles 0/6 Stereotaxis heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
-0.08%
Terugkoop Rendement
Totaal aandeelhoudersrendement -0.08% Toekomstig dividendrendement n/a Dividendgroei n/a Volgende betaaldatum dividend n/a Ex-dividenddatum n/a Dividend per aandeel n/a Uitbetalingsratio n/a
Recente updates van dividend en inkoop
Toon alle updates Stereotaxis, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 23
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 14
Insufficient new directors Aug 01
Stereotaxis, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 23
Stereotaxis Announces the Appointment of Nachum 'Homi' Shamir to Its Board of Directors Jul 19
Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System May 31
Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024 May 15 Stereotaxis, Inc. (NYSEAM:STXS) entered into a definitive share purchase agreement to acquire APT EP Inc. May 14
Stereotaxis, Inc. to Report Q1, 2024 Results on May 13, 2024 Apr 23
New minor risk - Shareholder dilution Apr 07
Stereotaxis, Inc., Annual General Meeting, May 15, 2024 Apr 05
Consensus EPS estimates fall by 20% Mar 27
Consensus revenue estimates decrease by 10%, EPS upgraded Mar 11
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 05
Stereotaxis, Inc. Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States Mar 05
Stereotaxis, Inc. to Report Q4, 2023 Results on Mar 04, 2024 Feb 21
New minor risk - Share price stability Feb 02
Stereotaxis Announces First Patients Successfully Treated Using Magic Ablation Catheter Jan 08
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 11
Price target decreased by 7.8% to US$4.70 Nov 09
Stereotaxis, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 18
No longer forecast to breakeven Aug 11
Stereotaxis, Inc. Reiterates Revenue Guidance for the Year 2023 Aug 11
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 11
Stereotaxis, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 18
Stereotaxis to Initiate First-In-Human Trial to Support CE Mark Application of Magic Catheter Jun 17
Price target decreased by 7.5% to US$4.90 Jun 16
Stereotaxis, Inc. Announces the First Treatment of Patients with Newly Launched Genesis Robotic Magnetic Navigation System At Advocate Christ Medical Center in Chicago, Illinois May 24
Consensus EPS estimates fall by 21% May 16
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 10
Forecast to breakeven in 2025 May 01
Price target decreased by 7.1% to US$5.42 Mar 06
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 06
No longer forecast to breakeven Mar 03
Stereotaxis, Inc. to Report Q4, 2022 Results on Mar 03, 2023 Feb 03
Stereotaxis Announces the Successful Treatment of Patients Using the Latest Genesis Robotic Magnetic Navigation Dec 21
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 19
Price target decreased to US$6.63 Nov 17
Insufficient new directors Nov 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 12
Stereotaxis, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 21
Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System Sep 14
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10
Stereotaxis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 20 Stereotaxis, Inc.(NYSEAM:STXS) dropped from Russell 2000 Dynamic Index
Price target decreased to US$9.42 May 13
Stereotaxis, Inc. Reiterates Revenue Guidance for the Full Year 2022 May 12
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 10
Price target decreased to US$10.25 Apr 27
Insufficient new directors Apr 27
Stereotaxis, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 15
Stereotaxis, Inc., Annual General Meeting, May 19, 2022 Apr 09
Consensus revenue estimates fall by 14% Mar 10
Stereotaxis, Inc. Provides Revenue Guidance for the Year 2022 Mar 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 05
No longer forecast to breakeven Mar 05
Price target decreased to US$10.25 Mar 04
Stereotaxis, Inc. to Report Q4, 2021 Results on Mar 03, 2022 Feb 15
Price target increased to US$11.25 Jan 14
Forecast to breakeven in 2024 Jan 07
Price target increased to US$11.30 Jan 06
Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.026 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: US$0.02 loss per share (vs US$0.032 loss in 2Q 2020) Aug 12
Insufficient new directors Aug 01
Price target increased to US$9.25 Jun 08
Forecast to breakeven in 2024 Jun 08
Stereotaxis, Inc. Provides Revenue Guidance for the Year 2021 May 11
Stereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building Mar 10
US$9.33 - That's What Analysts Think Stereotaxis, Inc. (NYSEMKT:STXS) Is Worth After These Results Feb 28
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.095 loss in FY 2019) Feb 28
Revenue beats expectations, earnings disappoint Feb 28
New 90-day high: US$7.46 Feb 25
New 90-day high: US$5.33 Feb 10
Stereotaxis, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 05
Is Stereotaxis (NYSEMKT:STXS) A Risky Investment? Jan 28
New 90-day high: US$5.32 Jan 06
Investors Who Bought Stereotaxis (NYSEMKT:STXS) Shares Five Years Ago Are Now Up 597% Dec 24
New 90-day high: US$4.60 Dec 11
New 90-day high: US$4.49 Nov 25
What Kind Of Investors Own Most Of Stereotaxis, Inc. (NYSEMKT:STXS)? Nov 19
Third quarter 2020 earnings released: US$0.026 loss per share Nov 11
New 90-day low: US$3.16 Oct 31
Stereotaxis, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 28
New 90-day low: US$3.18 Sep 25 Stereotaxis, Inc. announced that it has received $21.812883 million in funding from a group of investors Stereotaxis, Inc. announced that it expects to receive $15.765832 million in funding from Sanderling Ventures, Alafi Capital Company LLC, Emerson Electric Co., EGS Healthcare Capital Partners, LLC, Cambridge Capital Management, LLC
New 90-day low - US$3.71 Aug 20
Price target raised to US$7.50 Aug 05
Stereotaxis, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 24
Stabiliteit en groei van betalingen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van STXS in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van STXS zijn gestegen.
Dividendrendement versus markt Stereotaxis Dividendrendement versus markt
Hoe verhoudt STXS dividendrendement zich tot de markt? Segment Dividendrendement Bedrijf (STXS) n/a Markt onderkant 25% (US) 1.3% Markt Top 25% (US) 4.3% Gemiddelde industrie (Medical Equipment) 1.7% Analist prognose (STXS) (tot 3 jaar) n/a
Opmerkelijk dividend: Het dividendrendement van STXS kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van STXS kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio STXS te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat STXS geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
